Company Announcements

– The review provides strong scientific rationale to support Alto’s drug development approach leveraging its Precision Psychiatry Platform –

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Feb. 3, 2026-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, "Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments," in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience’s leadership team, Patricio O’Donnell, M.D., Ph.D, and Amit Etkin, M.D., Ph.D., as well as Husseini Manji, M.D., former global head of therapeutics, neuroscience at Janssen and a member of Alto’s board of directors.

The article consolidates extensive clinical and translational evidence demonstrating that disrupted neuroplasticity—spanning synaptic, cellular, and circuit-level dysfunction—is a shared biological driver across multiple high-burden psychiatric disorders, including major depressive disorder, schizophrenia, PTSD, and addiction.

The review concludes that therapeutic efficacy across pharmacologic, neuromodulatory, and behavioral interventions consistently converges on restoration of neuroplasticity, supporting plasticity as a causal, measurable, and druggable mechanism, rather than a descriptive or correlational concept. This framework helps explain both treatment resistance and durable clinical response, and provides a unifying biological rationale for next-generation psychiatric drug development.

The authors further highlight a critical industry gap: the historical absence of translatable biomarkers that directly index plasticity changes in humans. Addressing this gap is positioned as essential to improving patient stratification, accelerating development timelines, and increasing probability of clinical success—core elements of Alto’s precision psychiatry platform.

“These insights validate Alto’s strategy of pairing therapies with objective, circuit-level biomarkers,” said Amit Etkin, M.D., Ph.D., president and chief executive officer at Alto Neuroscience. “Moreover, we believe this publication underscores Alto’s leadership in translating rigorous neuroscience into differentiated, biomarker-driven clinical programs—which underpin the Company’s long-term platform value and relevance across multiple large psychiatric indications.”

The article appears in the American Journal of Psychiatry (2026), and can be found online here.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions.

Forward-Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “look forward,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to statements regarding Alto’s expectations about the potential benefits, activity, effectiveness, tolerability, and safety of its product candidates and Precision Psychiatry Platform (“Platform”); Alto’s expectations with regard to the general design and results of its research and development programs and clinical trials; and other statements that are not historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including uncertainties inherent in the initiation, progress and completion of clinical trials and clinical development of Alto’s product candidates, and other important factors, any of which could cause Alto’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled “Risk Factors” in each of Alto’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and Alto’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law.

Availability of Information on Alto’s Website

Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260203088315/en/

Investor and Media Contact:
Nick Smith
investors@altoneuroscience.com
media@altoneuroscience.com

Source: Alto Neuroscience, Inc.